Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder
ConclusionThe present results demonstrated that patients with EBV-PTLD may benefit from CAR-T therapy and that the toxicity is manageable. Further studies are needed to verify these findings.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Rituxan | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants